Clinical Trial Update: A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

A Phase 2 study assessing safety and effect of combining ABT-450/r with ABT-267 in adults with chronic hepatitis C; study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-267
• ABT-450/r (paritaprevir/ritonavir)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2015-08-04